Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis

被引：0
|
作者：
Ogdie, Alexis [1 ]
Mease, Philip [2 ,3 ]
Nantel, Francois [4 ]
Lavie, Frederic [5 ]
Sharaf, Mohamed [6 ]
Rampakakis, Emmanouil [7 ]
Marzo-Ortega, Helena [8 ,9 ]
Gossec, Laure [10 ]
机构：
[1] Univ Penn, Perelman Sch Med, Dept Med, Philadelphia, PA USA
[2] Providence St Joseph Hlth, Swedish Med Ctr, Seattle, WA USA
[3] Univ Washington, Sch Med, Seattle, WA USA
[4] Nantel MedSci Consult, Montreal, PQ, Canada
[5] Janssen Cilag Global Med Affairs, Immunol Global Med Affairs, Issy Les Moulineaux, France
[6] Middle East FZ LLC, Johnson & Johnson, Dubai, U Arab Emirates
[7] McGill Univ, Dept Pediat Sci Affairs, JSS Med Res Inc, Montreal, PQ, Canada
[8] Leeds Teaching Hosp NHS Trust, NIHR Leeds Biomed Res Ctr, Leeds, W Yorkshire, England
[9] Univ Leeds, Leeds Inst Rheumat & Musculoskeletal Med, Leeds, W Yorkshire, England
[10] Sorbonne Univ, Paris, France
来源：
ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷
关键词：
IMPORTANT-DIFFERENCE;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0583
引用
收藏
页码：1184 / 1187
页数：4
相关论文
共 50 条
  • [21] COMPARISON OF CLINICAL AND RADIOLOGIC TREATMENT OUTCOMES FOR PATIENTS WITH MODERATE VS. SEVERE PSORIATIC ARTHRITIS DISEASE ACTIVITY AT BASELINE: POST-HOC ANALYSIS OF ADEPT
    Mease, P. J.
    Kavanaugh, A.
    Perdok, R.
    Kupper, H.
    Lavie, F.
    RHEUMATOLOGY, 2010, 49 : I51 - I51
  • [22] Impact of risankizumab on achieving minimal clinically important differences in patient-reported disease activity, fatigue, and pain among patients with active psoriatic arthritis: Analysis of 2 phase 3 clinical trials
    Kristensen, Lars Erik
    Soliman, Ahmed
    Papp, Kim
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB68 - AB68
  • [23] Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
    Ana-Maria Orbai
    Philip J. Mease
    Philip S. Helliwell
    Oliver FitzGerald
    Dona L. Fleishaker
    Rajiv Mundayat
    Pamela Young
    BMC Rheumatology, 6
  • [24] Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies
    Orbai, Ana-Maria
    Mease, Philip J.
    Helliwell, Philip S.
    FitzGerald, Oliver
    Fleishaker, Dona L.
    Mundayat, Rajiv
    Young, Pamela
    BMC RHEUMATOLOGY, 2022, 6 (01)
  • [25] IMPROVEMENT IN KEY PSORIATIC ARTHRITIS CORE DOMAINS WITH GUSELKUMAB TREATMENT IN AN ENRICHED POPULATION OF ACR20 NONRESPONDERS AT WEEK 24: POST HOC ANALYSIS OF TWO PHASE 3 STUDIES
    Mcgonagle, D.
    Haaland, D.
    Helliwell, P.
    Marrache, M.
    Shawi, M.
    Rampakakis, E.
    Nash, P.
    Irazoque-Palazuelos, F.
    Kavanaugh, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1772 - 1773
  • [26] Effect of Tofacitinib on Efficacy and Patient-Reported Outcomes in Psoriasis Patients with Baseline Psoriatic Arthritis: A Pooled Analysis of 2 Phase 3 Studies
    Bachelez, Herve
    Griffiths, Christopher E. M.
    Papp, Kim
    Hall, Stephen
    Merola, Joseph F.
    Feldman, Steven R.
    Khraishi, Majed
    Tallman, Anna
    Tan, Huaming
    Hsu, Ming-Ann
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [27] Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study
    Coates, Laura C.
    Gossec, Laure
    Zimmermann, Miriam
    Shawi, May
    Rampakakis, Emmanouil
    Shiff, Natalie J.
    Kollmeier, Alexa P.
    Xu, Xie L.
    Nash, Peter
    Mease, Philip J.
    Helliwell, Philip S.
    RMD OPEN, 2024, 10 (01):
  • [28] Minimal Important Difference (MID), Minimal Detectable Change (MDC), and Disease Activity Thresholds for Two Novel Composite Instruments (3VAS, 4VAS) in Patients with Psoriatic Arthritis: Pooled Analysis of Three Phase 3 Studies
    Tillett, William
    Coates, Laura
    Vis, Marijn
    Merola, Joseph
    Soriano, Enrique R.
    Perate, Michelle
    Shawi, May
    Zimmermann, Miriam
    Rampakakis, Emmanouil
    Sharaf, Mohamed
    Nash, Peter
    Helliwell, Philip
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 2013 - 2015
  • [29] MINIMAL IMPORTANT DIFFERENCE (MID), MINIMAL DETECTABLE CHANGE (MDC), AND DISEASE ACTIVITY THRESHOLDS FOR TWO NOVEL COMPOSITE INSTRUMENTS (3VAS, 4VAS) IN PATIENTS WITH PSORIATIC ARTHRITIS: POOLED ANALYSIS OF THREE PHASE 3 STUDIES
    Tillett, W.
    Coates, L.
    Vis, M.
    Merola, J. F.
    Soriano, E.
    Perate, M.
    Shawi, M.
    Zimmermann, M.
    Rampakakis, E.
    Sharaf, M.
    Nash, P.
    Helliwell, P.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 343 - 344
  • [30] Effect of guselkumab on serum biomarkers in patients with active psoriatic arthritis and inadequate response to tumor necrosis factor inhibitors: results from the COSMOS phase 3b study
    Schett, Georg
    Chen, Warner
    Gao, Sheng
    Chakravarty, Soumya D.
    Shawi, May
    Lavie, Frederic
    Zimmermann, Miriam
    Sharaf, Mohamed
    Coates, Laura C.
    Siebert, Stefan
    ARTHRITIS RESEARCH & THERAPY, 2023, 25 (01)
12345